Abstract
Acute kidney injury (AKI) is relatively common in patients undergoing transcatheter aortic valve implantation (TAVI) and has been associated with increased mortality and worse outcomes. The administration of iodinated contrast media in an elderly population with increased rates of chronic kidney injury and heart failure, the risk of hemodynamic compromise and the use of large catheters intra-procedurally make patients undergoing TAVI particularly vulnerable to renal insults and AKI. Furthermore, these patients are commonly exposed to iodinated contrast media during diagnostic and possible interventional procedures pre-TAVI. While risk factors such as baseline comorbidities are non-modifiable, others such as administration of nephrotoxic medications, the type and amount of contrast medium and the catheters size can be avoided, modified and improved. In addition, numerous other interventions such as volume expansion and possibly medications can prevent contrast related kidney injury. In this review, we sought to focus on strategies aiming at reducing the incidence of TAVI-related AKI.
Keywords: Transcatheter aortic valve implantation, Acute kidney injury, Contrast induced nephropathy
Current Pharmaceutical Design
Title:Strategies to Avoid TAVI-related Acute Kidney Injury
Volume: 22 Issue: 13
Author(s): Polydoros N. Kampaktsis, Dmitriy N. Feldman and Konstantinos Charitakis
Affiliation:
Keywords: Transcatheter aortic valve implantation, Acute kidney injury, Contrast induced nephropathy
Abstract: Acute kidney injury (AKI) is relatively common in patients undergoing transcatheter aortic valve implantation (TAVI) and has been associated with increased mortality and worse outcomes. The administration of iodinated contrast media in an elderly population with increased rates of chronic kidney injury and heart failure, the risk of hemodynamic compromise and the use of large catheters intra-procedurally make patients undergoing TAVI particularly vulnerable to renal insults and AKI. Furthermore, these patients are commonly exposed to iodinated contrast media during diagnostic and possible interventional procedures pre-TAVI. While risk factors such as baseline comorbidities are non-modifiable, others such as administration of nephrotoxic medications, the type and amount of contrast medium and the catheters size can be avoided, modified and improved. In addition, numerous other interventions such as volume expansion and possibly medications can prevent contrast related kidney injury. In this review, we sought to focus on strategies aiming at reducing the incidence of TAVI-related AKI.
Export Options
About this article
Cite this article as:
Kampaktsis N. Polydoros, Feldman N. Dmitriy and Charitakis Konstantinos, Strategies to Avoid TAVI-related Acute Kidney Injury, Current Pharmaceutical Design 2016; 22 (13) . https://dx.doi.org/10.2174/1381612822666151208120522
DOI https://dx.doi.org/10.2174/1381612822666151208120522 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipid Metabolism and Relevant Disorders to Female Reproductive Health
Current Medicinal Chemistry Primary Heart Involvement in Systemic Sclerosis
Current Rheumatology Reviews Cellular Protection and Therapeutic Potential of Tocotrienols
Current Pharmaceutical Design Long Noncoding RNA OIP5-AS1 Overexpression Promotes Viability and Inhibits High Glucose-Induced Oxidative Stress of Cardiomyocytes by Targeting MicroRNA-34a/SIRT1 Axis in Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Cannabinoids and Cardiovascular Disease: The Outlook for Clinical Treatments
Current Vascular Pharmacology Branched-chain Amino Acid Oxidation in Skeletal Muscle – Physiological and Clinical Importance of its Modulation by Reactant Availability
Current Nutrition & Food Science Cellular and Biochemical Alterations Caused by Artificial Depletion of Glutathione
Current Enzyme Inhibition Role of Exosomes in Breast Cancer Management: Evidence-Based Review
Current Cancer Drug Targets ACE Inhibition of Plant Alkaloids Targeted Approach for Selective Inhibition
Mini-Reviews in Organic Chemistry Entresto, a New Panacea for Heart Failure?
Cardiovascular & Hematological Agents in Medicinal Chemistry Preterm Labour: An Overview of Current and Emerging Therapeutics
Current Medicinal Chemistry The Role of LVOT-VTI Measurement in the Evaluation of Systolic Heart Function in Pulmonary ICU Patients
Current Respiratory Medicine Reviews Human Cytomegalovirus US28: A Functionally Selective Chemokine Binding Receptor
Infectious Disorders - Drug Targets Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews Biological Active Ingredients of Traditional Chinese Herb Astragalus membranaceus on Treatment of Diabetes: A Systematic Review
Mini-Reviews in Medicinal Chemistry Reversal of Informational Entropy and the Acquisition of Germ-like Immortality by Somatic Cells
Current Aging Science Impact of Aging on the Angiogenic Potential of the Myocardium: Implications for Angiogenic Therapies with Emphasis on Sirtuin Agonists
Recent Patents on Cardiovascular Drug Discovery Impact of Matrix Metalloproteinases on Atherosclerosis
Current Drug Targets Application of Current Diagnostic Criteria for Arrhythmogenic Right Ventricular Cardiomyopathy in Every Day Clinical Practice
Current Pharmaceutical Design Individualizing Calcineurin Inhibitor Therapy in Renal Transplantation - Current Limitations and Perspectives
Current Pharmaceutical Design